폐경 여성에서 타목시펜 사용 후 발견된 거대 자궁내막용종
A GIANT ENDOMETRIAL POLYP WITH TAMOXIFEN THERAPY IN POSTMENOPAUSAL WOMAN
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
타목시펜은 합성 비스테로이드성 호르몬으로 유방조직에서는 항에스트로겐으로 작용하여 수년간 유방암 환자의 보조요법제로 사용됐다. 그러나 에스트로겐 농도가 낮은 폐경 여성에서 에스트로겐 활성을 가져 자궁내막 병변을 일으킨다. 이 중 자궁내막용종은 타목시펜 치료를 받는 폐경 여성에서 가장 흔히 발견되는 자궁내막 병변으로 저자들은 폐경 후 유방암 환자에서 술후 보조요법으로 약 5년간 타목시펜 치료를 받은 후 발견된 거대 자궁내막용종을 경험하였기에 문헌 고찰과 함께 보고하는 바이다.
Abstract
Tamoxifen is a synthetic non-steroid anti-estrogen that has been used effectively for several years in the adjuvant treatment of breast cancer. But, the drug has been associated with development of endometrial poylp, hyperplasia and adenocarcinoma possibly mediated through its agonistic estrogen properties during the menopausal period in which estrogens are at a low level. Endometrial polyp has been described as the most common endometrial pathology in association with postmenopausal tamoxifen treatment. We present the case of woman with a giant endometrial polyp of uncommon dimension who was receiving adjuvant tamoxifen for 5 years after breast cancer surgery.
참고문헌 (13)
- Bergman L, "Risk and prognosis of endometrial cancer after tamoxifen for breast cancer, Assessment of Liver and Endometrial cancer Risk following Tamoxifen", Lancet, 356, pp.881~887 (2000), Comprehensive Cancer Centres’ ALERT Group
- Erdemoglu E, "Tamoxifen and giant endometrial polyp", Eur J Gynaecol Oncol, 29, pp.198~199 (2008)
- Killackey MA, "Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens", Cancer Treat Rep, 69, pp.237~238 (1985)
- 이경은, "타목시펜 치료를 받는 유방암 환자에서 자궁내막의 병리", Obstetrics & Gynecology Science, 51(7), pp.757~765 (2008), 대한산부인과학회
- Cohen I, "Significance of secondary ultrasonographic endometrial thicken ing in postmenopausal tamoxifen-treated women", Cancer, 94, pp.3101~3106 (2002)
- Cohen I, "Time-dependent effect of tamoxifen therapy on endometrial pathology in asymptomatic postmenopausal breast cancer patients", Int J Gynecol Pathol, 15, pp.152~157 (1996)
- Bonadona V, "Tamoxifen and endometrial cancer: the results from a multicenter case controlled study", Bull Cancer, 83, pp.507~508 (1996)
- Fisher B, "Endometrial cancer in tamoxifen-treated breast cancer patients: fi ndings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14", J Natl Cancer Inst, 86, pp.527~537 (1994)
- McGurgan P, "Does tamoxifen therapy affect the hormone receptor expression and cell proliferation indices of endometrial polyps? An immunohistochemical comparison of endometrial polyps from postmenopausal women exposed and not exposed to tamoxifen", Maturitas, 54, pp.252~259 (2006)
- Choe BH, "Cases with endometrial polyp and endocervical polyp associated with tamoxifen use", Korean J Obstet Gynecol, 43, pp.725~730 (2000)
- Franchi M, "Endometrial thickness in tamoxifen-treated patients: an independent predictor of endometrial disease", Obstet Gynecol, 93, pp.1004~1008 (1999)
- Neven P, "Tamoxifen and the uterus and endometrium", Lancet, 1, pp.375~ (1989)
- Mourits MJ, "Discrepancy between ultrasonography and hysteroscopy and histology of endometrium in postmenopausal breast cancer patients using tamoxifen", Gynecol Oncol, 73, pp.21~26 (1999)